person · Reporting owner

Kauffman Michael

Disclosed activity across 6 companies

Tapewire entity: 37452
SEC CIK: 0001364719

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802	Director	June 13, 2019	June 14, 2019
KYNTRA BIO, INC.KYNB · Entity 7431	Director	June 12, 2026	June 17, 2026
Karyopharm Therapeutics Inc.KPTI · Entity 781	Director	February 28, 2022	March 02, 2022
Verastem, Inc.VSTM · Entity 5242	Director · President of Development	January 06, 2026	January 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INFINITY PHARMACEUTICALS, INC.

Report date June 13, 2019 · Filed June 14, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2029-06-12	Direct	30,000	Reported balance After 2019-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-13 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

KYNTRA BIO, INC.

Report date June 12, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2036-06-11	Direct	7,000	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Karyopharm Therapeutics Inc.

Report date February 28, 2022 · Filed March 02, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	713,757	Ending reported balance After 2022-02-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-02-28 · Grant · Acquired 21,000 · Balance 719,983 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Row 2 · 2022-02-28 · Sale · Disposed 6,226 · Balance 713,757 F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	898,131	Reported balance After 2022-02-28 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-02-28 · Sale · Disposed 6,226 · Balance 898,131 F4: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2032-02-27	Direct	27,000	Reported balance After 2022-02-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-02-28 · Grant · Acquired 27,000 · Balance 27,000 F5: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F5: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Verastem, Inc.

Report date January 06, 2026 · Filed January 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2036-01-06	Direct	200,000	Reported balance After 2026-01-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-06 · Grant · Acquired 200,000 · Balance 200,000 F1: The stock option vests 33.33% of the shares on the first anniversary of January 6, 2026 (the "Grant Date"), and an additional 8.33% will vest at the end of each successive three-month period following the first anniversary of the Grant Date until the third anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest) provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests 33.33% of the shares on the first anniversary of January 6, 2026 (the "Grant Date"), and an additional 8.33% will vest at the end of each successive three-month period following the first anniversary of the Grant Date until the third anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest) provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Adicet Bio, Inc.

Report date August 21, 2024 · Filed August 23, 2024

Section 16 reporting ended · disclosed 2024-08-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-11-16	Direct	0	Reported balance After 2024-08-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-21 · Disposition to issuer · Disposed 37,000 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2031-11-16	Direct	37,000	Reported balance After 2024-08-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-08-21 · Grant · Acquired 37,000 · Balance 37,000 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2032-06-01	Direct	0	Reported balance After 2024-08-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-21 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2032-06-01	Direct	18,500	Reported balance After 2024-08-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-21 · Grant · Acquired 18,500 · Balance 18,500 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2033-05-31	Direct	0	Reported balance After 2024-08-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-21 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.20 · Expires 2033-05-31	Direct	26,400	Reported balance After 2024-08-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-21 · Grant · Acquired 26,400 · Balance 26,400 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.

Filing footnotes · ownership attribution and instrument terms

F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

F3: The shares subject to this option are fully vested and exercisable as of the date hereof.

Kezar Life Sciences, Inc.

Report date May 11, 2026 · Filed May 11, 2026

Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-11 transaction · row 1 1 source row Row 1 · 2026-05-11 · Other · Disposed 6,369 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.10 · Expires 2028-04-15	Direct	Reported balance After 2026-05-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-11 · Disposition to issuer · Disposed 389 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2033-06-14	Direct	Reported balance After 2026-05-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-11 · Disposition to issuer · Disposed 3,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2034-06-19	Direct	Reported balance After 2026-05-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2035-06-17	Direct	Reported balance After 2026-05-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2029-06-24	Direct	Reported balance After 2026-05-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2030-06-23	Direct	Reported balance After 2026-05-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2031-06-27	Direct	Reported balance After 2026-05-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2032-06-15	Direct	Reported balance After 2026-05-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement")

F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.

F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (Right to Buy) · Derivative	8,896	Not disclosed Strike: $2.28	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,896 Underlying: Common Stock · 8,896 shares Expires 2029-06-24 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (Right to Buy) · Derivative	8,896	Not disclosed Strike: $7.63	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,896 shares Expires 2029-06-24 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:36 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $2.64	$0.00	Disclosure SEC source: 0001209191-23-037927 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/15/2024, subject to Reporting Person continuing to provide service through such date. Read SEC document
June 01, 2023 Filed Jun 2, 2023 21:48 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	26,400	$0.00 Strike: $5.20	$0.00	Disclosure SEC source: 0001209191-23-033959 · doc4.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 01, 2023 Filed Jun 2, 2023 21:48 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantCommon Stock	5,900	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033959 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document
May 15, 2023 Filed May 16, 2023 20:34 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	62,500	$0.00 Strike: $0.42	$0.00	Disclosure SEC source: 0001104659-23-061426 · tm2315836-7_4seq1.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2023 to April, 2024 and the last installment shall vest on the earlier of (i) the day before the 2024 Annual Meeting of Stockholders is held or (ii) May 31, 2024, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:10 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	62,500	$0.00 Strike: $1.11	$0.00	Disclosure SEC source: 0001104659-22-074308 · tm2219034-7_4seq1.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document
June 16, 2022 Filed Jun 17, 2022 22:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (right to buy) · Derivative	26,000	$0.00 Strike: $4.80	$0.00	Disclosure SEC source: 0001209191-22-038050 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/16/2023, subject to Reporting Person continuing to provide service through such date. Read SEC document
June 02, 2022 Filed Jun 3, 2022 20:38 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	18,500	$0.00 Strike: $11.49	$0.00	Disclosure SEC source: 0001209191-22-034088 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common stock · 18,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
May 12, 2022 Filed Dec 20, 2022 21:07 UTC Amendment	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	62,500	$0.00 Strike: $1.07	$0.00	Disclosure SEC source: 0001104659-22-128633 · tm2232937-5_4aseq1.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-05-12 F1 · security: On June 24, 2022 the Reporting Person filed a Form 4 reporting a stock option grant which incorrectly stated an exercise price of $1.11, a transaction date of June 22, 2022 and an expiration date of June 22, 2032. This amendment is being filed to reflect the corrected exercise price of $1.07, transaction date of May 12, 2022 and expiration date of May 12, 2032. F2 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document
February 28, 2022 Filed Mar 2, 2022 20:18 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	GrantStock Option (right to buy) · Derivative	27,000	$0.00 Strike: $10.33	$0.00	Disclosure SEC source: 0001209191-22-014624 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-02-27 F5 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document
February 28, 2022 Filed Mar 2, 2022 20:18 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	6,226	$10.24	$63,738.68	Disclosure SEC source: 0001209191-22-014624 · doc4.xml · nonDerivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 898,131 F4 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 28, 2022 Filed Mar 2, 2022 20:18 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	6,226	$10.24	$63,738.68	Disclosure SEC source: 0001209191-22-014624 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,757 F2 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 28, 2022 Filed Mar 2, 2022 20:18 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	GrantCommon Stock	21,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-014624 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,983 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Read SEC document
February 17, 2022 Filed Feb 22, 2022 21:14 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	9,088	$12.12	$110,177.46	Disclosure SEC source: 0001209191-22-011636 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 904,357 F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
February 17, 2022 Filed Feb 22, 2022 21:14 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	9,079	$12.12	$110,068.35	Disclosure SEC source: 0001209191-22-011636 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,983 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
February 07, 2022 Filed Feb 9, 2022 22:24 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	6,707	$9.86	$66,144.43	Disclosure SEC source: 0001209191-22-008124 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 913,445 F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
February 07, 2022 Filed Feb 9, 2022 22:24 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	6,764	$9.86	$66,706.57	Disclosure SEC source: 0001209191-22-008124 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 708,062 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
January 03, 2022 Filed Jan 5, 2022 23:51 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $5.91	$0.00	Disclosure SEC source: 0001209191-22-001964 · doc4.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,896 Underlying: Common Stock · 5,000 shares Expires 2028-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
January 03, 2022 Filed Jan 5, 2022 23:51 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	SaleCommon Stock	5,000	$16.45	$82,250.00	Disclosure SEC source: 0001209191-22-001964 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,690 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.164 to $16.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 03, 2022 Filed Jan 5, 2022 23:51 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Exercise / conversionCommon Stock	5,000	$5.91	$29,550.00	Disclosure SEC source: 0001209191-22-001964 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 17, 2021 Filed Nov 18, 2021 12:13 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (right to Buy) · Derivative	37,000	$0.00 Strike: $9.39	$0.00	Disclosure SEC source: 0001209191-21-065375 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2031-11-16 F1 · derivative.exercise_date: These shares shall vest in thirty-six (36) equal monthly installments beginning November 17, 2021. Read SEC document
June 28, 2021 Filed Jun 30, 2021 22:47 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (Right to Buy) · Derivative	26,000	$0.00 Strike: $5.59	$0.00	Disclosure SEC source: 0001209191-21-044085 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/28/2022, subject to Reporting Person continuing to provide service through such date. Read SEC document
June 28, 2021 Filed Jun 30, 2021 17:56 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0001104659-21-087398 · tm2121071-1_4seq1.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document
March 18, 2021 Filed Mar 23, 2021 11:48 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	4,000	$12.39	$49,552.80	Disclosure SEC source: 0001209191-21-022486 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,826 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.29 to $12.56, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 25, 2021 Filed Mar 2, 2021 01:09 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	GrantStock Option (right to buy) · Derivative	153,500	$0.00 Strike: $14.56	$0.00	Disclosure SEC source: 0001209191-21-015481 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2031-02-24 F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document
February 25, 2021 Filed Mar 2, 2021 01:09 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	GrantStock Option (right to buy) · Derivative	153,500	$0.00 Strike: $14.56	$0.00	Disclosure SEC source: 0001209191-21-015481 · doc4.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2031-02-24 F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document
February 25, 2021 Filed Mar 2, 2021 01:09 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	GrantCommon Stock	57,200	$0.00	$0.00	Disclosure SEC source: 0001209191-21-015481 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 920,152 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F3 · balance_after: The spouse of the reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 776,452 shares of common stock. Read SEC document
February 25, 2021 Filed Mar 2, 2021 01:09 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	GrantCommon Stock	57,200	$0.00	$0.00	Disclosure SEC source: 0001209191-21-015481 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,826 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 575,126 shares of common stock. Read SEC document
February 18, 2021 Filed Feb 23, 2021 01:09 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	9,495	$14.83	$140,822.24	Disclosure SEC source: 0001209191-21-012960 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 776,452 F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
February 18, 2021 Filed Feb 23, 2021 01:09 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	9,495	$14.83	$140,822.24	Disclosure SEC source: 0001209191-21-012960 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,126 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
February 15, 2021 Filed Feb 17, 2021 23:44 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionRestricted Stock Units · Derivative	21,800	$0.00	$0.00	Disclosure SEC source: 0001209191-21-011484 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 43,600 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F7 · derivative.exercise_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F7 · derivative.expiration_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document
February 15, 2021 Filed Feb 17, 2021 23:44 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionRestricted Stock Units · Derivative	21,800	$0.00	$0.00	Disclosure SEC source: 0001209191-21-011484 · doc4.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,600 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F6 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F6 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document
February 15, 2021 Filed Feb 17, 2021 23:44 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionCommon Stock	21,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 785,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document
February 15, 2021 Filed Feb 17, 2021 23:44 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionCommon Stock	21,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document
February 11, 2021 Filed Feb 17, 2021 23:44 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	6,642	$15.52	$103,077.20	Disclosure SEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 3 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 764,147 F4 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F5 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
February 11, 2021 Filed Feb 17, 2021 23:44 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	6,601	$15.52	$102,440.92	Disclosure SEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,821 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document
February 05, 2021 Filed Feb 10, 2021 01:28 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionRestricted Stock Units · Derivative	14,300	$0.00	$0.00	Disclosure SEC source: 0001209191-21-009070 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 42,900 Underlying: Common Stock · 14,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document
February 05, 2021 Filed Feb 10, 2021 01:28 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionRestricted Stock Units · Derivative	14,300	$0.00	$0.00	Disclosure SEC source: 0001209191-21-009070 · doc4.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,900 Underlying: Common Stock · 14,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document
February 05, 2021 Filed Feb 10, 2021 01:28 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionCommon Stock	14,300	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-009070 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 770,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document
February 05, 2021 Filed Feb 10, 2021 01:28 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionCommon Stock	14,300	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-009070 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document
October 12, 2020 Filed Oct 14, 2020 21:56 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionStock Option (right to buy) · Derivative	6,076	$0.00 Strike: $0.03	$0.00	Disclosure SEC source: 0001209191-20-054822 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 6,076 shares Expires 2020-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document
October 12, 2020 Filed Oct 14, 2020 21:56 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionStock Option (right to buy) · Derivative	1,424	$0.00 Strike: $0.03	$0.00	Disclosure SEC source: 0001209191-20-054822 · doc4.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 1,424 shares Expires 2020-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document
October 12, 2020 Filed Oct 14, 2020 21:56 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	7,500	$14.89	$111,682.50	Disclosure SEC source: 0001209191-20-054822 · doc4.xml · nonDerivative · entry 3 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.71 to $15.16, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
October 12, 2020 Filed Oct 14, 2020 21:56 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionCommon Stock	6,076	$0.03	$200.51	Disclosure SEC source: 0001209191-20-054822 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 763,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document
October 12, 2020 Filed Oct 14, 2020 21:56 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionCommon Stock	1,424	$0.03	$46.99	Disclosure SEC source: 0001209191-20-054822 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 757,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document
August 17, 2020 Filed Aug 18, 2020 22:07 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionStock Option (right to buy) · Derivative	1,477	$0.00 Strike: $0.03	$0.00	Disclosure SEC source: 0001209191-20-047279 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,076 Underlying: Common Stock · 1,477 shares Expires 2020-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document
August 17, 2020 Filed Aug 18, 2020 22:07 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	SaleCommon Stock	1,477	$15.00	$22,155.00	Disclosure SEC source: 0001209191-20-047279 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document
August 17, 2020 Filed Aug 18, 2020 22:07 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionCommon Stock	1,477	$0.03	$48.74	Disclosure SEC source: 0001209191-20-047279 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 757,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document
July 15, 2020 Filed Jul 17, 2020 20:26 UTC	Karyopharm Therapeutics Inc. KPTI · Entity 781	Exercise / conversionStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $0.03	$0.00	Disclosure SEC source: 0001209191-20-042845 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,424 Underlying: Common Stock · 7,500 shares Expires 2020-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.